Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

This study has been completed.
Information provided by (Responsible Party):
Tillotts Pharma AG Identifier:
First received: January 28, 2010
Last updated: September 16, 2013
Last verified: April 2013